Cancer name Hepatocellular Carcinoma
Cancer Type LIHC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment CCR2 antagonist
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature TAMs
Official Symbol NA
Mode of action CE_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Flow cytometric analysis of Hepa1-6 tumours showeda 71.4% reduction of TAMs and a 2.52-fold increase of CD8+T cells in mice treated with the CCR2 antagonist.
PMID 26452628
Title Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.